A patient death overshadowed the first data from a human trial of the company’s allogeneic Car-T therapy CTX110.
The Swiss group moves to start a further trial of prasinezumab, but this will not be phase III.
An attempt to abrogate the placebo response does not seem to have gone as planned.
Slower labs are to be paid less for Covid-19 tests, but will the move actually speed things up?
A mid-stage clinical failure raises more doubts about Galapagos’s pipeline and the wisdom of Gilead’s $5bn deal last year.